Specific, Irreversible Inactivation of the Epidermal Growth Factor Receptor and erbB2, by a New Class of Tyrosine Kinase Inhibitor - Fry, David W.; Bridges, Alexander J.; Denny, William A.; Doherty, Annette; Greis, Kenneth D.; Hicks, James L.; Hook, Kenneth E.; Keller, Paul R.; Leopold, Wilbur R.; Loo, Joseph A.; McNamara, Dennis J.; Nelson, James M.; et al. (Proceedings of the National Academy of Sciences - PNAS, 1998)
Keywords: Animals; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Average linear density; Binding Sites - genetics; Biological Sciences; Carcinoma; Cell Line; Cysteine - chemistry; Enzyme Inhibitors - chemistry; Enzyme Inhibitors - pharmacology; Enzymes; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - chemistry; ErbB Receptors - genetics; Fibroblast growth factors; Growth factor receptors; Humans; Inactivation; Inhibitory concentration 50; Medical treatment; Mice; Mice, Nude; Models, Molecular; Mutagenesis, Site-Directed; Neoplasm Transplantation; Neoplasms, Experimental - drug therapy; Neoplasms, Experimental - metabolism; Pharmacology; Phosphorylation; Protein Conformation; Protein-Tyrosine Kinases - antagonists & inhibitors; Protein-Tyrosine Kinases - chemistry; Protein-Tyrosine Kinases - genetics; Proteins; Quinazolines - chemistry; Quinazolines - pharmacology; Receptor, ErbB-2 - antagonists & inhibitors; Receptor, ErbB-2 - chemistry; Receptor, ErbB-2 - genetics; Receptors; Recombinant Fusion Proteins - antagonists & inhibitors; Recombinant Fusion Proteins - genetics; Skin; Transplantation, Heterologous; Tumor Cells, Cultured; Tumors